Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dash"

1818 News Found

PM-JAY public dashboard gets revamped with new features
News | June 07, 2022

PM-JAY public dashboard gets revamped with new features

The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress


NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)
News | May 30, 2022

NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)

The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level


NATCO Pharma to acquire Dash Pharmaceuticals
News | December 15, 2021

NATCO Pharma to acquire Dash Pharmaceuticals

The cash consideration for the acquisition is US$ 18 million.


HealthPlix releases Prescription Summary Dashboard for doctors
Healthcare | December 15, 2021

HealthPlix releases Prescription Summary Dashboard for doctors

Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them


Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Clinical Trials | February 07, 2026

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke


FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
News | February 07, 2026

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy


Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
News | February 07, 2026

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


£1bn London Cancer Hub expansion wins planning approval
R&D | February 07, 2026

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing